Cassava Sciences (SAVA)

Cassava Sciences' mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer's disease.

Company profile

Ticker

SAVA

Exchange

NASDAQ

Website

www.paintrials.com

CEO

Remi Barbier

Incorporated

Delaware

Location

Texas

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie ...

Former names

PAIN THERAPEUTICS INC

SEC CIK

0001069530

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Austin Innovation Park, LLC ...

IRS number

911911336

SAVA stock data

1M 1Y 5Y

News

From Benzinga Pro

5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise

6 Jun 22

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

12 Health Care Stocks Moving In Tuesday's Intraday Session

31 May 22

5 Short Squeeze Candidates To Watch This Week: 2 Former SPACs Join Leaderboard With BigBear.AI Topping List

24 May 22

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

How Is The Market Feeling About Cassava Sciences?

12 May 22

Recap: Cassava Sciences Q1 Earnings

5 May 22

Press releases

From Benzinga Pro

Bragar Eagel & Squire, P.C. Is Investigating GoodRx, Cassava, Ebix, and the WWE and Encourages Investors to Contact the Firm

24 Jun 22

NEW YORK, June 24, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against GoodRx Holdings, Inc. (NASDAQ:GDRX), Cassava

Thinking about buying stock in Tonix Pharmaceuticals, View, vTv Therapeutics, TherapeuticsMD, or Cassava Sciences?

1 Jun 22

NEW YORK, June 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TNXP, VIEW, VTVT, TXMD, and SAVA.

Bragar Eagel & Squire, P.C. Is Investigating Medallion, Corcept, RBB, and Cassava and Encourages Investors to Contact the Firm

29 May 22

NEW YORK, May 29, 2022 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Medallion Financial Corp. (NASDAQ:MFIN),

Global Psychedelics Market Is Expected To Reach $8 Billion By 2029

24 May 22

Bragar Eagel & Squire, P.C. Is Investigating Cassava, Dentsply Sirona, IonQ, and Singularity Future and Encourages Investors to Contact the Firm

22 May 22

Investment data

Data from SEC filings

Securities sold

Number of investors

Calendar

5 May 22

26 Jun 22

31 Dec 22

Financial summary

Financial statements Chart SAVA financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	209.69M	209.69M	209.69M	209.69M	209.69M	209.69M
Cash burn (monthly)	7.91M	6.04M	5.94M	3.93M	7.84M	4.29M
Cash used (since last report)	22.72M	17.34M	17.05M	11.28M	22.51M	12.3M
Cash remaining	186.97M	192.35M	192.64M	198.41M	187.18M	197.39M
Runway (months of cash)	23.6	31.8	32.4	50.5	23.9	46.1

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

SAVA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
6 Jun 22	Remi Barbier	Common Stock	Payment of exercise	Dispose F	No	No	27.93	54,720	1.53M	767,717
6 Jun 22	Remi Barbier	Common Stock	Option exercise	Acquire M	No	No	23.38	65,368	1.53M	822,437
6 Jun 22	Remi Barbier	Common Stock Common Stock	Option exercise	Dispose M	No	No	23.38	65,368	1.53M	0
27 May 22	Nadav Friedmann	Common Stock	Payment of exercise	Dispose F	No	No	26.66	21,498	573.14K	70,534
27 May 22	Nadav Friedmann	Common Stock	Payment of exercise	Dispose F	No	No	26.66	3,071	81.87K	92,032
27 May 22	Nadav Friedmann	Common Stock	Option exercise	Acquire M	No	No	23.38	24,513	573.11K	95,103
27 May 22	Nadav Friedmann	Common Stock	Option exercise	Acquire M	No	No	23.38	3,501	81.85K	70,590
27 May 22	Nadav Friedmann	Common Stock Common Stock	Option exercise	Dispose M	No	No	23.38	24,513	573.11K	0
27 May 22	Nadav Friedmann	Common Stock Common Stock	Option exercise	Dispose M	No	No	23.38	3,501	81.85K	0
25 Apr 22	Remi Barbier	Common Stock	Option exercise	Acquire M	Yes	No	16.31	4,669	76.15K	376,112

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

SAVA institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	0	0
Opened positions	0	0
Closed positions	0	0
Increased positions	0	0
Reduced positions	0	0

13F shares	Current	Prev Q	Change
Total value	0	0
Total shares	0	0
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change

Largest transactions	Shares	Bought/sold	Change

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Abbott Laboratories • Mylan • AMGEN • Acura Pharmaceuticals • Biogen • Roche • Elite Pharmaceuticals • Endo Health Solutions • Novartis • Anavex Life Sciences

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: category, confined, County, CUNY, divert, dosage, enquiry, exploratory, federal, high, lawsuit, length, lingering, maximize, monthly, motion, nature, package, packaging, pending, percent, policy, population, preliminary, preserve, primary, publicly, Puerto, putative, quality, rational, rental, replaced, resolution, Rico, segment, staffing, stay, stayed, subsidiary, suite, typically, University, verification, volatility, York

Removed: Additionally, ASU, beginning, beneficial, blinded, campaign, cognitively, compare, complexity, conclude, detected, drain, effort, FASB, fast, franchise, goal, independent, initiative, intact, intention, journal, lower, multiply, outdated, overt, Overview, quantitative, recently, reduce, redundant, remain, simple, Simplifying, superseded, supplemental, Topic, trillion, triple, tx, untreated, upcoming, young

From filing 10-Q 2022 Q1

Financial reports

View all